Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Between the two industry giants, Fidelity’s robust platform pulls slightly ahead Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback